• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

    3/10/23 11:42:36 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email
    SC 13G/A 1 tm239149d1_sc13g.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C.  20549

     

     

     

    SCHEDULE 13G 

    (Amendment no. 5)

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments 

    Thereto Filed Pursuant to § 240.13d-2.

     

    Under the Securities Exchange Act of 1934

     

    Allarity Therapeutics, Inc. 

    (Name of Issuer)

     

                  COMMON STOCK, PAR VALUE $0.0001PER SHARE              

    (Title of Class of Securities)

     

              016744104         

    (CUSIP Number)

     

                            March 2, 2023                      

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b) 

    ¨  Rule 13d-1(c) 

    ¨  Rule 13d-1(d)

     

     

     

     

     

    Page 1 of 6 Pages

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 2 of 6 Pages

             
    1)

    NAME OF REPORTING PERSON

     

    Forsakringsaktiebolaget Avanza Pension

     

    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       o

    (b)       o  

    3)

    SEC USE ONLY

     

     

    4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Stockholm, Sweden

     

    NUMBER

    OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5)

    SOLE VOTING POWER

     

    1,367,568

    6)

    SHARED VOTING POWER

     

     

    7)

    SOLE DISPOSITIVE POWER

     

     

    8)

    SHARED DISPOSITIVE POWER

     

    1,367,568

    9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,367,568

    10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

    11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4,56 %

    12)

    TYPE OF REPORTING PERSON

     

    FI

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 3 of 6 Pages

     

    Item 1(a). Name of Issuer:

     

    Allarity Therapeutics, Inc

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    24 School, St, 2Nd Floor

    BOSTON, MA, 02108

    United States

     

    Item 2(a).Name of Person Filing:

     

    Forsakringsaktiebolaget Avanza Pension

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    Box 13129

    Stockholm, Sweden 10303

     

    Item 2(c). Citizenship:

     

    Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, Par Value $0.0001 per share

     

    Item 2(e). CUSIP Number:  016744104

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)

     

      (c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)

     

      (d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

     

      (e) ¨ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

     

      (f) ¨ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)

     

      (g) ¨ Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G)

      

      (h) ¨ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

     

      (i) ¨ Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 4 of 6 Pages

     

      (j) x A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)
           
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K)

     

    Item 4.

    Ownership.

    (This 13G is based on 30,000,000 shares of Common Stock outstanding)

     

      (a) Amount beneficially owned:  1,367,568

     

      (b)

    Percent of class: 4,56 %

     

     

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:  1,367,568

     

      (ii) Shared power to vote or to direct the vote:  None

     

      (iii) Sole power to dispose or to direct the disposition of:  None

     

      (iv) Shared power to dispose or to direct the disposition of: 1,367,568

     

      Number and Percentage
    of Shares Beneficially Owned
    Date
      4,56 % / 1,367,568 March 2, 2023

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 5 of 6 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 6 of 6 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    March 10, 2023  
       
       
    Marie Andersson / Middle Office  
    Name/Title  

     

     

    Get the next $ALLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action

           TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced a research collaboration with the Indiana Biosciences Research Institute (IBRI). The collaboration is aimed primarily at further deepening the Company's mechanistic understanding of the dual mechanism of action of stenoparib. Stenoparib is a novel, orally available small-molecule inhibitor of PAR

      6/4/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

               TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP®) companion diagnostic (CDx) toward potential FDA approval. It builds on encouraging data from Allarity'

      6/2/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

               TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business development and licensing conference for executives of biotechnology and pharmaceutical companies, taking place May 14–15 in San Diego, CA. Registrants can request one-on-one meetings with Tho

      5/12/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    SEC Filings

    See more
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/5/25 8:09:43 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/3/25 8:05:26 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      5/13/25 8:01:52 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Leadership Updates

    Live Leadership Updates

    See more

    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

        Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio

      11/14/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

      Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk's U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced seve

      10/3/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      - New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the appointment of Alex Epshinsky as the Company's new Chief Financial Officer (CFO), and that the Company has granted equity awards on September 12, 2024 as a material inducement to the employment of Mr. Epshinsky. Mr. Epshinsky is a Chartered Public Accountant (CPA) and brings nearly a decade of financial leadership experience in the biotech and

      9/13/24 8:45:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:10:53 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Benjamin Laura

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:09:04 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Mclaughlin Gerald W.

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:07:13 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      11/13/24 9:24:34 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Allarity Therapeutics Inc.

      SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)

      8/29/24 3:57:47 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      2/12/24 9:52:15 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Financials

    Live finance-specific insights

    See more
    • Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

      - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s

      5/14/24 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Reports Third Quarter 2022 Financial Results

      Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:

      11/15/22 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

      Press release        Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. ("Oncoheroes"), a clini

      1/3/22 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care